Amplyx Pharmaceuticals
San Diego, US · Delaware corporation · 5 known investors
Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)
Founders & leadership
MM
Mitchell MutzExecutive
Board
CM
Chrysa MineoBoard director
JF
Jack FlorioBoard director
EH
Elaine HeronBoard director
SV
Santosh VetticadenBoard director
KT
Karen TalmadgeBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$116.6M disclosed across 3 rounds · 2015–2017
▶$91.3MraisedJan 2020 · 28 investors · PharmaceuticalsRule 506(b)
▶$91.3MraisedJan 2020 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael GreyDirector
- Ciara KennedyExecutive Officer, Director
- Paul GrintDirector
- Elaine HeronDirector
- Johan KordelDirector
- Edward MathersDirector
- Anand MehraDirector
- Alan FuhrmanExecutive Officer
- Mike HodgesExecutive Officer
- Niall ODonnellDirector
- Offering amount
- $102.7M
- Amount sold
- $91.3M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.7MraisedDec 2015 · 25 investors · PharmaceuticalsRule 506(b)
▶$23.7MraisedDec 2015 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Elaine HeronDirector
- Niall ODonnellDirector
- Ed MathersDirector
- Ciara KennedyExecutive Officer
- Michael GreyExecutive Officer, Director
- Mitchell MutzExecutive Officer
- Offering amount
- $49.2M
- Amount sold
- $23.7M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2015 · 13 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedAug 2015 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chrysa MineoDirector
- Jack FlorioDirector
- Elaine HeronDirector
- Mitchell MutzExecutive Officer, Director
- Santosh VetticadenDirector
- Karen TalmadgeDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $50K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Amplyx Pharmaceuticals do?
- Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)
- Who are Amplyx Pharmaceuticals's investors?
- Amplyx Pharmaceuticals's investors include New Enterprise Associates (NEA), Pappas Capital, RiverVest Venture Partners, Sofinnova Ventures, Sofinnova Venture Partners.
- How much funding has Amplyx Pharmaceuticals raised?
- Amplyx Pharmaceuticals has disclosed $116.6M raised across 3 rounds.
- Where is Amplyx Pharmaceuticals headquartered?
- Amplyx Pharmaceuticals is headquartered in San Diego, US.